MET and non-small cell lung carcinoma: Furthermore, an analysis of 1586 NSCLC patients with paired PD-L1 testing and next-generation sequencing revealed that KRAS mutations, unlike EGFR mutations, were significantly associated with high PD-L1 expression, a trend also observed in tumors harboring tumor protein P53 (TP53) and MET mutations [15].